[EN] BISANTHRAPYRAZOLES AS ANTI-CANCER AGENTS<br/>[FR] BISANTHRAPYRAZOLES COMME AGENTS ANTICANCER
申请人:UNIV MANITOBA
公开号:WO2009004496A2
公开(公告)日:2009-01-08
Disclosed are novel bisanthrapyrazoles that likely act as bisintercalators and topoisomerase Ilα inhibitors. These compounds show potent inhibition of cancer cell growth, and certain bisanthrapyrazoles bind to DNA more tightly than doxorubicin, a known intercalating anti-cancer drug. Molecular modeling techniques are also disclosed that allow one to predict the DNA binding strength of various intercalators.
The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds
作者:Brian B. Hasinoff、Rui Zhang、Xing Wu、Lynn J. Guziec、Frank S. Guziec、Kyle Marshall、Jack C. Yalowich
DOI:10.1016/j.bmc.2009.04.072
日期:2009.7
A series of amide-coupled bisanthrapyrazole derivatives of 7-chloro-2-[2-[(2-hydroxyethyl)methylamino]ethyl]anthra[1,9-cd]pyrazol-6(2H)-one (AP9) were designed using molecular modeling and docking and synthesized in order to develop an anticancer drug that formed a strongly binding bisintercalation complex with DNA. Concentration dependency for the increase in the DNA melting temperature was used to
一系列酰胺偶联的7-氯-2- [2-[([2-羟乙基)甲基氨基]乙基]蒽[1,9 - cd ]吡唑-6(2 H)的联蒽并吡唑衍生物使用分子建模和对接设计一个(AP9)并合成,以开发一种抗癌药物,该药物与DNA形成强结合双嵌入复合物。DNA融解温度升高的浓度依赖性用于确定DNA结合强度以及新合成的类似物是否发生双嵌入。还测量了化合物抑制人红白血病K562细胞系生长和抑制DNA拓扑异构酶IIα的脱级活性的能力。最后,通过测量拓扑异构酶IIα介导的DNA双链切割,评估了这些化合物作为拓扑异构酶II毒物的能力。所有的双蒽吡唑均在低微摩尔范围内抑制K562细胞的生长和拓扑异构酶IIα。具有两个或三个亚甲基接头的化合物与DNA形成双插层络合物,并与阿霉素一样强或更强地结合。总之,设计,合成了一组新的酰胺偶联双插入蒽吡唑化合物,并评估了其作为潜在抗癌剂的理化和生物学特性。